Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2007
11/28/2007EP1302104B1 P300 transgenic animal
11/28/2007EP1261322B1 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
11/28/2007EP1115863B1 Ucp4
11/28/2007EP1006794B1 A method for treating or preventing alzheimer's disease
11/28/2007EP0983222B1 Pharmaceutical agents for the treatment of cerebral amyloidosis
11/28/2007CN200980750Y Medicine releasing structure with nanometer-level hole used for medicine eluting apparatus
11/28/2007CN200980749Y Local porous medicine releasing structure with medicine used medicine eluting apparatus
11/28/2007CN200980747Y Medicine releasing structure for medicine eluting apparatus
11/28/2007CN101080499A Genomic screen for epigenetically silenced tumor suppressor genes
11/28/2007CN101080250A Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same
11/28/2007CN101080232A Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and hmg CoA reductase inhibitors
11/28/2007CN101077335A Anticancer composition containing tyrosine kinase inhibitor
11/28/2007CN101077334A Anticancer composition containing tyrosine kinase inhibitor
11/28/2007CN100351253C Pyrrolo [2,3-d] pyrimidine compounds as immunosuppressive agents
11/28/2007CN100351241C Stable polymorph of N-(3-ethynylphenylamino)-6,7-bis (2-methoxyethoxy)-4-quinazolinamine hydrochloride, method of production and pharmaceutical uses thereof
11/28/2007CN100351234C Bis-heterocyclic compounds with antitumour and chemosensitising activity
11/28/2007CN100350979C Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
11/28/2007CN100350977C Medicinal compositions
11/28/2007CN100350975C Anticarcinogen composition
11/28/2007CN100350974C Anticarcinogen composition
11/28/2007CN100350971C Stimulation of bone growth with thrombin peptide derivatives
11/28/2007CN100350970C 因子 Factor
11/28/2007CN100350968C Modification of feeding behavior
11/28/2007CN100350919C Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria
11/27/2007US7301068 Nonhuman model animal of Th2-mediated hyperimmune response
11/27/2007US7301023 Immunosuppressants; grafting of organs; rheumatic diseases
11/27/2007US7301005 Immunomodulatory peptides derived from heat shock proteins and uses thereof
11/27/2007US7300944 Alzheimer's disease, bipolar disorder, diabetes, dementia, stroke, schizophrenia, depression, hair loss, cancer
11/27/2007US7300941 Non-imidazole compounds
11/27/2007US7300927 Method for treating or preventing Alzheimer's disease
11/27/2007US7300922 Enhancing or inhibiting the biological activity of nucleic acid ligands by administrating a modulator, to change the binding of the nucleic acid ligand for its target or degrading or cleaving
11/27/2007US7300765 SC6 for diagnosis of cancers
11/27/2007US7300662 Local delivery system is coated with rapamycin or other suitable drug, agent or compound and delivered intraluminally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiography, lower systemic toxicity
11/27/2007US7300656 Treatment of inflammatory bowel disease with IFN-gamma inhibitors
11/27/2007US7300654 Method of treating corneal transplant rejection in high risk keratoplasty patients
11/27/2007US7300653 Method of treating corneal transplant rejection
11/27/2007US7300652 Contacting cell expressing kidney injury-molecule-1 (KIM-1) cell surface polypeptide with an effective amount of an isolated antibody or antigen-binding-fragment thereof that binds to the extracellular domain of the human KIM-1 polypeptide
11/27/2007US7300428 Tissue volume reduction
11/27/2007CA2340728C Methods of treating hypertension and compositions for use therein
11/27/2007CA2271683C Coated particles, methods of making and using
11/27/2007CA2253613C Therapeutic treatment for vegf related occular diseases
11/27/2007CA2186892C Methods for treating pulmonary vasoconstriction and asthma
11/22/2007WO2007134055A1 Antibacterial extracellular polysaccharide solvating system
11/22/2007WO2007132947A1 Bcl-xL TRANSGENIC ANIMAL AND UTILIZATION OF THE SAME
11/22/2007WO2007132882A1 Pharmaceutical composition for treating or preventing hcv infection
11/22/2007WO2007132867A1 Prophylactic and therapeutic agent for cancer
11/22/2007WO2007132841A1 Fused heterocyclic compound and use thereof
11/22/2007WO2007132546A1 Pharmaceutical containing thiazole derivative as active ingredient
11/22/2007WO2007132234A1 Pharmaceutical compositions comprising 5-aminolevulinic acid
11/22/2007WO2007132221A1 Combined anticancer pyrimidine-thiazole aurora kinase inhibitors
11/22/2007WO2007131737A2 Medication against breast cancer and related diseases
11/22/2007WO2007131736A2 Use of 4, 17 beta-dihydroxyandrost-4-ene-3-one for treating cancers
11/22/2007WO2007131689A2 Pharmaceutical combinations comprising a mtor inhibitor and a raf kinase inhibitor
11/22/2007WO2007131345A1 Genetic risk factor in sod1 and sfrs15 in renal disease, diabetic cataract, cardiovascular disease and longevity
11/22/2007WO2007131253A2 Use of combination preparations comprising antifungal agents
11/22/2007WO2007106317A3 Pharmaceutical combinations of hcv-protease and -ires inhibitors
11/22/2007WO2007098868A8 Use of moxifloxacin in combination with cefixime for treatment of infectious diseases caused by gram-positive and gram-negative pathogens
11/22/2007WO2007093183A3 Use of a compound that enhances gabaa-ergic neurotransmission for the treatment of inflammatory diseases
11/22/2007WO2007084670A3 Specific therapy using integrin ligands for treating cancer
11/22/2007WO2007024599A3 Comination of a hypnotic agent and r(+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenl)ethyl]-4-piperidinemethanol and therapeutic application thereof
11/22/2007WO2007022412A3 Combination therapy for preventing angiogenesis comprising a inhibitor ofhif-1 and a further anti-angiogenic agent
11/22/2007WO2006101486A3 Bacteriocins and novel bacterial strains
11/22/2007WO2002047726A3 Pharmaceutical composition containing an active with a hemolytic action and a surfactant
11/22/2007WO2000018212A8 Platelet-derived growth factor c, dna coding therefor, and uses thereof
11/22/2007US20070270504 Identification of Therapeutic Agents Using Genetic Fingerprinting
11/22/2007US20070270490 Use of (-)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
11/22/2007US20070270489 Remedy for Cartilage-Related Diseases
11/22/2007US20070270481 Novel combination of anticholineric and beta mimetics for the treatment of respiratory diseases
11/22/2007US20070270459 Overactive bladder treating drug
11/22/2007US20070270448 Methods of Using and Compositions Comprising a Jnk Inhibitor for the Treatment and Management of Asbestos-Related Diseases and Disorders
11/22/2007US20070270441 Combination
11/22/2007US20070270432 Novel Method
11/22/2007US20070270429 Function Inhibitor of Effector Cell
11/22/2007US20070270404 Tuberculosis treatment using pleuromutilin derivatives
11/22/2007US20070270392 Use of a Cyclopentenone Prostaglandin for Delaying the Onset and/or Preventing the Continuation of Labour
11/22/2007US20070270388 Uses of 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic acid
11/22/2007US20070270372 arresting heart of subject in need of heart surgery by exposing heart to effective amounts of a compound chosen from a potassium channel opener, a potassium channel agonist, an adenosine receptor agonist, and a local anaesthetic under conditions sufficient for heart to be arrested
11/22/2007US20070270353 Intrathecal administration of ziconotide, an Omega-conopeptide, and the anitoxidant methionine, and an analgesic selected from morphine, hydromorphone, fentanyl, sufentanil, and buprenorphine; ziconotide retains its potency and is physically and chemically compatible with the analgesic
11/22/2007US20070270351 Methods and Reagents for Regulation of Cellular Responses in Biological Systems
11/22/2007US20070270350 Methods and Compositions for the Prevention and Treatment of Inflammatory Diseases or Conditions
11/22/2007US20070269847 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer
11/22/2007US20070269539 Ginkgo Biloba Extract as a Treatment for Therapeutic-Induced Neurotoxicity
11/22/2007US20070269534 Methods of treating skin to enhance therapeutic treatment thereof
11/22/2007US20070269530 Disinfectant and method of making
11/22/2007US20070269528 A Omega-conopeptide, and the anitoxidant methionine, and either clonidine or baclofen; ziconotide retains its potency and is physically and chemically compatible with the analgesic; for intrathecal administration
11/22/2007US20070269501 Immunotherapeutic Agent for the Combined Treatment of Tuberculosis in Association With Other Drugs
11/22/2007US20070269420 Compounds, Compositions and Methods for Treatment and Prophylaxis of Hepatitis C Viral Infections and Associated Diseases
11/22/2007US20070269413 Transdiscal administration of high affinity anti-MMP inhibitors
11/22/2007US20070269407 Use of interleukin-19 to treat cervical cancer
11/22/2007US20070269406 Transcatheter tumor immunoembolization
11/22/2007US20070269372 monoclonal antibodies or fragment thereof which binds a cell surface glycoprotein antigen located on the surface of human multiple myeloma tumor cells; for therapeutic, screening, diagnostic and cell purification purposes
11/22/2007DE102006023560A1 Use of biocomplex-reaction pattern in vertebrate cells preparation e.g. primary therapy for idiopathic pulmonary fibrosis and as adjuvant therapy for cytostatics, for steroidal and non-steroidal anti-inflammatory drugs
11/22/2007CA2652345A1 Methods and compositions for treatment of sleep apnea related applications
11/22/2007CA2652333A1 Pharmaceutical composition for treating or preventing hcv infection
11/22/2007CA2652328A1 Prophylactic and therapeutic agent for cancer
11/22/2007CA2652057A1 Medication against breast cancer and related diseases
11/22/2007CA2651813A1 Neurogenesis by modulating angiotensin
11/22/2007CA2651765A1 A medicament containing a thiazole derivative as an active ingredient
11/22/2007CA2651726A1 Use of combination preparations, comprising antimycotics
11/22/2007CA2651646A1 Antibacterial extracellular polysaccharide solvating system comprising a metal ion sequestering agent
1 ... 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 ... 1151